TITLE:
Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen

CONDITION:
Breast Neoplasms

INTERVENTION:
Exemestane

SUMMARY:

      This is an open-label, multicenter, randomized (1:1 randomization ratio) study of either
      exemestane or exemestane plus celecoxib in postmenopausal women with ABC having progressed
      on tamoxifen.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: Female
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Postmenopausal female patient with histologically or cytologically confirmed breast
             cancer having progressed on Tamoxifen.

          -  Advanced disease: patients with advanced breast carcinoma with disease progression
             who had progressed/relapsed following > 8 weeks of treatment with Tamoxifen for
             advanced disease; or progressed during adjuvant Tamoxifen for at least 6 or 12 months
             depending on receptor status; or progressed within 12 months from completion of
             adjuvant treatment with Tamoxifen.

          -  at least one measurable lesion

        Exclusion Criteria:

          -  More than one previous chemotherapy and/or more than one hormonotherapy for advanced
             disease.

          -  Previous hormonotherapy for advanced disease other than Tamoxifen.

          -  Myocardial infarction within previous 6 mo
      
